VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Promising novel antibody therapies for AML

Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares an update on the most promising novel antibody therapies for the treatment of acute myeloid leukemia (AML). Dr Ravandi discusses CD33- targeting antibodies, in particular gemtuzumab ozogamicin, and other promising targets, such as CD123. Dr Ravandi also outlines the potential benefits of bispecific T-cell engagers such as flotetuzumab, AMG 330, AMG 673, AMG 472 and XmAb14045. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter